NASDAQ:ACOR
$0.98
(
0.84%
)
Friday, 3rd Feb 2023
Acorda Therapeutics Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $0.670 | $1.18 | Friday, 3rd Feb 2023 ACOR stock ended at $0.98. This is 0.84% more than the trading day before Thursday, 2nd Feb 2023. During the day the stock fluctuated 7.22% from a day low at $0.97 to a day high of $1.04. |
| 90 days | $0.460 | $1.18 | |
| 52 weeks | $0.261 | $2.29 |
Historical Acorda Therapeutics prices
| Date | Open | High | Low | Close | Volume |
| 2023-02-03 | $0.97 | $1.04 | $0.97 | $0.98 | 128 148 |
| 2023-02-02 | $0.98 | $1.00 | $0.93 | $0.97 | 250 029 |
| 2023-02-01 | $0.96 | $0.96 | $0.90 | $0.92 | 136 437 |
| 2023-01-31 | $0.89 | $0.95 | $0.89 | $0.95 | 143 071 |
| 2023-01-30 | $0.93 | $0.96 | $0.89 | $0.89 | 159 802 |
| 2023-01-27 | $0.93 | $0.95 | $0.90 | $0.94 | 210 251 |
| 2023-01-26 | $0.99 | $1.02 | $0.94 | $0.95 | 189 588 |
| 2023-01-25 | $0.95 | $1.00 | $0.94 | $0.98 | 109 806 |
| 2023-01-24 | $0.95 | $0.99 | $0.89 | $0.94 | 216 541 |
| 2023-01-23 | $0.97 | $1.00 | $0.93 | $0.99 | 227 671 |
| 2023-01-20 | $1.00 | $1.00 | $0.92 | $0.98 | 324 557 |
| 2023-01-19 | $1.02 | $1.18 | $0.97 | $0.98 | 955 900 |
| 2023-01-18 | $0.88 | $1.02 | $0.87 | $1.00 | 710 500 |
| 2023-01-17 | $0.85 | $0.90 | $0.85 | $0.90 | 117 406 |
| 2023-01-13 | $0.93 | $0.93 | $0.83 | $0.84 | 282 051 |
| 2023-01-12 | $0.88 | $0.94 | $0.86 | $0.93 | 157 205 |
| 2023-01-11 | $0.93 | $0.95 | $0.87 | $0.87 | 283 553 |
| 2023-01-10 | $0.780 | $0.96 | $0.780 | $0.88 | 561 300 |
| 2023-01-09 | $0.770 | $0.80 | $0.750 | $0.800 | 454 405 |
| 2023-01-06 | $0.720 | $0.790 | $0.670 | $0.770 | 206 700 |
| 2023-01-05 | $0.80 | $0.83 | $0.700 | $0.713 | 462 085 |
| 2023-01-04 | $0.792 | $0.80 | $0.715 | $0.80 | 186 464 |
| 2023-01-03 | $0.778 | $0.790 | $0.687 | $0.785 | 208 415 |
| 2022-12-30 | $0.680 | $0.778 | $0.660 | $0.767 | 934 393 |
| 2022-12-29 | $0.590 | $0.700 | $0.590 | $0.665 | 279 923 |
| 2022-12-28 | $0.607 | $0.700 | $0.565 | $0.625 | 276 282 |
| 2022-12-27 | $0.580 | $0.650 | $0.557 | $0.620 | 366 185 |
| 2022-12-23 | $0.531 | $0.580 | $0.530 | $0.580 | 75 447 |
| 2022-12-22 | $0.536 | $0.572 | $0.528 | $0.528 | 132 348 |
| 2022-12-21 | $0.530 | $0.565 | $0.501 | $0.528 | 103 301 |
| 2022-12-20 | $0.542 | $0.580 | $0.520 | $0.550 | 59 784 |
| 2022-12-19 | $0.600 | $0.600 | $0.510 | $0.542 | 143 222 |
| 2022-12-16 | $0.570 | $0.580 | $0.550 | $0.580 | 83 658 |
| 2022-12-15 | $0.523 | $0.580 | $0.520 | $0.550 | 127 564 |
| 2022-12-14 | $0.541 | $0.589 | $0.520 | $0.522 | 228 257 |
| 2022-12-13 | $0.544 | $0.590 | $0.535 | $0.550 | 155 521 |
| 2022-12-12 | $0.540 | $0.575 | $0.510 | $0.560 | 90 341 |
| 2022-12-09 | $0.590 | $0.590 | $0.550 | $0.575 | 76 320 |
| 2022-12-08 | $0.530 | $0.600 | $0.510 | $0.560 | 57 873 |
| 2022-12-07 | $0.580 | $0.590 | $0.460 | $0.532 | 305 481 |
| 2022-12-06 | $0.573 | $0.591 | $0.511 | $0.573 | 177 774 |
| 2022-12-05 | $0.600 | $0.633 | $0.588 | $0.588 | 154 997 |
| 2022-12-02 | $0.600 | $0.640 | $0.600 | $0.611 | 139 673 |
| 2022-12-01 | $0.639 | $0.650 | $0.610 | $0.627 | 77 389 |
| 2022-11-30 | $0.600 | $0.645 | $0.600 | $0.639 | 161 712 |
| 2022-11-29 | $0.630 | $0.650 | $0.600 | $0.618 | 185 528 |
| 2022-11-28 | $0.600 | $0.640 | $0.600 | $0.619 | 120 344 |
| 2022-11-25 | $0.600 | $0.630 | $0.600 | $0.610 | 45 497 |
| 2022-11-23 | $0.600 | $0.630 | $0.600 | $0.617 | 127 497 |
| 2022-11-22 | $0.540 | $0.600 | $0.540 | $0.573 | 170 200 |
About Acorda Therapeutics
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS p... ACOR Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
